281 related articles for article (PubMed ID: 12778137)
21. In vitro expansion of polyclonal T-cell subsets for adoptive immunotherapy by recombinant modified vaccinia Ankara.
La Rosa C; Wang Z; Lacey SF; Lalimarmo MM; Krishnan A; Longmate J; Diamond DJ
Exp Hematol; 2006 Apr; 34(4):497-507. PubMed ID: 16569596
[TBL] [Abstract][Full Text] [Related]
22. Clinical grade generation of hexon-specific T cells for adoptive T-cell transfer as a treatment of adenovirus infection after allogeneic stem cell transplantation.
Feuchtinger T; Richard C; Joachim S; Scheible MH; Schumm M; Hamprecht K; Martin D; Jahn G; Handgretinger R; Lang P
J Immunother; 2008; 31(2):199-206. PubMed ID: 18481389
[TBL] [Abstract][Full Text] [Related]
23. Dendritic cells modified to express fractalkine/CX3CL1 in the treatment of preexisting tumors.
Nukiwa M; Andarini S; Zaini J; Xin H; Kanehira M; Suzuki T; Fukuhara T; Mizuguchi H; Hayakawa T; Saijo Y; Nukiwa T; Kikuchi T
Eur J Immunol; 2006 Apr; 36(4):1019-27. PubMed ID: 16525992
[TBL] [Abstract][Full Text] [Related]
24. Augmentation of post transplant immunity: antigen encounter at the time of hematopoietic stem cell transplantation enhances antigen-specific donor T-cell responses in the post transplant repertoire.
Mori S; Kocak U; Shaw JL; Mullen CA
Bone Marrow Transplant; 2005 Apr; 35(8):793-801. PubMed ID: 15750607
[TBL] [Abstract][Full Text] [Related]
25. Listeria monocytogenes activated dendritic cell based vaccine for prevention of experimental tumor in mice.
Khamisabadi M; Arab S; Motamedi M; Khansari N; Moazzeni SM; Gheflati Z; Hadjati J
Iran J Immunol; 2008 Mar; 5(1):36-44. PubMed ID: 18319523
[TBL] [Abstract][Full Text] [Related]
26. Antitumor effect of intratumoral administration of bone marrow-derived dendritic cells transduced with wild-type p53 gene.
Murakami T; Tokunaga N; Waku T; Gomi S; Kagawa S; Tanaka N; Fujiwara T
Clin Cancer Res; 2004 Jun; 10(11):3871-80. PubMed ID: 15173096
[TBL] [Abstract][Full Text] [Related]
27. In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) T cell responses.
Esslinger C; Chapatte L; Finke D; Miconnet I; Guillaume P; Lévy F; MacDonald HR
J Clin Invest; 2003 Jun; 111(11):1673-81. PubMed ID: 12782670
[TBL] [Abstract][Full Text] [Related]
28. [Immunotherapy against tumor with dendritic cell sensitized by necrotic tumor tissue after microwave coagulation therapy].
Yao LC; Yang RJ
Zhonghua Yi Xue Za Zhi; 2007 Sep; 87(36):2552-6. PubMed ID: 18067832
[TBL] [Abstract][Full Text] [Related]
29. Lentivirally transduced dendritic cells as a tool for cancer immunotherapy.
Breckpot K; Dullaers M; Bonehill A; van Meirvenne S; Heirman C; de Greef C; van der Bruggen P; Thielemans K
J Gene Med; 2003 Aug; 5(8):654-67. PubMed ID: 12898635
[TBL] [Abstract][Full Text] [Related]
30. Ex vivo expansion of hematopoietic cells and their clinical use.
Aglietta M; Bertolini F; Carlo-Stella C; De Vincentiis A; Lanata L; Lemoli RM; Olivieri A; Siena S; Zanon P; Tura S
Haematologica; 1998 Sep; 83(9):824-48. PubMed ID: 9825579
[TBL] [Abstract][Full Text] [Related]
31. Similar immune responses and antitumor effects of murine dendritic cells loaded with either exogenous or endogenous-synthesized protein.
Lacave R; Masurier C; Guigon M; Lemoine FM; Klatzmann D; Colombo BM
Int J Oncol; 2003 Dec; 23(6):1747-53. PubMed ID: 14612950
[TBL] [Abstract][Full Text] [Related]
32. Sequential delivery of interferon-alpha gene and DCs to intracranial gliomas promotes an effective antitumor response.
Tsugawa T; Kuwashima N; Sato H; Fellows-Mayle WK; Dusak JE; Okada K; Papworth GD; Watkins SC; Gambotto A; Yoshida J; Pollack IF; Okada H
Gene Ther; 2004 Nov; 11(21):1551-8. PubMed ID: 15343358
[TBL] [Abstract][Full Text] [Related]
33. Combined intratumoral injection of bone marrow-derived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors.
Tong Y; Song W; Crystal RG
Cancer Res; 2001 Oct; 61(20):7530-5. PubMed ID: 11606390
[TBL] [Abstract][Full Text] [Related]
34. Eradication of established B-cell lymphoma by CD19-specific murine T cells is dependent on host lymphopenic environment and can be mediated by CD4+ and CD8+ T cells.
Cheadle EJ; Hawkins RE; Batha H; Rothwell DG; Ashton G; Gilham DE
J Immunother; 2009 Apr; 32(3):207-18. PubMed ID: 19242379
[TBL] [Abstract][Full Text] [Related]
35. In vivo antitumor effect of CD40L-transduced tumor cells as a vaccine for B-cell lymphoma.
Briones J; Timmerman J; Levy R
Cancer Res; 2002 Jun; 62(11):3195-9. PubMed ID: 12036933
[TBL] [Abstract][Full Text] [Related]
36. Immortalized dendritic cell line with efficient cross-priming ability established from transgenic mice harboring the temperature-sensitive SV40 large T-antigen gene.
Ebihara S; Endo S; Ito K; Ito Y; Akiyama K; Obinata M; Takai T
J Biochem; 2004 Sep; 136(3):321-8. PubMed ID: 15598888
[TBL] [Abstract][Full Text] [Related]
37. Potent vaccine therapy with dendritic cells genetically modified by the gene-silencing-resistant retroviral vector GCDNsap.
Nabekura T; Otsu M; Nagasawa T; Nakauchi H; Onodera M
Mol Ther; 2006 Feb; 13(2):301-9. PubMed ID: 16311073
[TBL] [Abstract][Full Text] [Related]
38. Generation of anti-tumour effector T cells from naïve T cells by stimulation with dendritic/tumour fusion cells.
Ishida A; Tanaka H; Hiura T; Miura S; Watanabe S; Matsuyama K; Kuriyama H; Tanaka J; Kagamu H; Gejyo F; Yoshizawa H
Scand J Immunol; 2007 Nov; 66(5):546-54. PubMed ID: 17953530
[TBL] [Abstract][Full Text] [Related]
39. Appropriate timing of CD40 ligation for RNA-Pulsed DCs to induce antitumor immunity.
Miura S; Kagamu H; Tanaka H; Yoshizawa H; Gejyo F
Scand J Immunol; 2008 Apr; 67(4):385-91. PubMed ID: 18282232
[TBL] [Abstract][Full Text] [Related]
40. Augmentation of antitumor immune responses after adoptive transfer of bone marrow derived from donors immunized with tumor lysate-pulsed dendritic cells.
Asavaroengchai W; Kotera Y; Koike N; Pilon-Thomas S; Mulé JJ
Biol Blood Marrow Transplant; 2004 Aug; 10(8):524-33. PubMed ID: 15282530
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
